

MONSANTO CO /NEW/
Form 8-K
September 23, 2015

As Filed with the Securities and Exchange Commission on September 23, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 23, 2015 (September 22, 2015)

MONSANTO COMPANY
(Exact Name of Registrant as Specified in its Charter)

Delaware (State of Incorporation)	001-16167 (Commission File Number)	43-1878297 (IRS Employer Identification No.)
--------------------------------------	---------------------------------------	---

800 North Lindbergh Boulevard
St. Louis, Missouri 63167
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (314) 694-1000

Not Applicable
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d.-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 22, 2015, Monsanto Company's Board of Directors elected Patricia D. Verduin, Ph.D. to the Board of Directors and appointed Dr. Verduin to its Science and Technology Committee and its Sustainability and Corporate Responsibility Committee. Dr. Verduin is the Vice President and Chief Technology Officer of Colgate Palmolive Company. Dr. Verduin will stand for election at the Company's 2016 annual meeting of shareowners.

In addition, the Board determined that Dr. Verduin is independent under the listing standards of the New York Stock Exchange ("NYSE") and the Board's charter and corporate governance guidelines.

Dr. Verduin will be entitled to receive the same compensation for service as a director as is provided to other directors of the Company under the Non-Employee Director Equity Incentive Compensation Plan (the "Plan"). The Plan was described in more detail in the Proxy Statement for our 2015 annual meeting. Under the Plan, Dr. Verduin will receive an annual retainer, which for fiscal 2016 is \$245,000. Half of the aggregate retainer is payable in deferred common stock, and the remainder is payable, at the election of each director, in the form of restricted common stock, deferred common stock, current cash and/or deferred cash. Pursuant to the Plan, Dr. Verduin was also provided a grant of restricted stock upon commencement of service as a member of the Board of Directors equal to the full annual base retainer divided by the closing price of a share of the Company's common stock on the commencement date, which amounted to 2,832 shares of restricted stock.

A press release announcing the election of Dr. Verduin as a director, as described above, is attached as Exhibit 99.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following documents are filed as exhibits to this report:

Exhibit 99 Press Release dated September 22, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 23, 2015

MONSANTO COMPANY

By: /s/ Michelle Bushore
Name: Michelle Bushore
Title: Assistant Secretary

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99	Press Release dated September 22, 2015